Miniatura

Fitxers

fonc-13-1197340.pdf (1.6 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2023-11-02

Llicència de publicació

cc by (c) Rosiñol, Laura et al., 2023
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/205802

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3389/fonc.2023.1197340

Resum

ObjectiveProviding the most efficacious frontline treatment for newly diagnosed multiple myeloma (NDMM) is critical for patient outcomes. No direct comparisons have been made between bortezomib + lenalidomide + dexamethasone (VRD) and bortezomib + thalidomide + dexamethasone (VTD) induction regimens in transplant-eligible NDMM.MethodsAn integrated analysis was performed using patient data from four trials meeting prespecified eligibility criteria: two using VRD (PETHEMA GEM2012 and IFM 2009) and two using VTD (PETHEMA GEM2005 and IFM 2013-04).ResultsThe primary endpoint was met, with VRD demonstrating a noninferior rate of at least very good partial response (>= VGPR) after induction vs VTD. GEM comparison demonstrated improvement in the >= VGPR rate after induction for VRD vs VTD (66.3% vs 51.2%; P = .00281) that increased after transplant (74.4% vs 53.5%). Undetectable minimal residual disease rates post induction (46.7% vs 34.9%) and post transplant (62.4% vs 47.3%) support the benefit of VRD vs VTD. Treatment-emergent adverse events leading to study and/or treatment discontinuation were less frequent with VRD (3%, GEM2012; 6%, IFM 2009) vs VTD (11%, IFM 2013-04).ConclusionThese results supported the benefit of VRD over VTD for induction in transplant-eligible patients with NDMM. The trials included are registered with ClinicalTrials.gov (NCT01916252, NCT01191060, NCT00461747, and NCT01971658).

Matèries

Mieloma múltiple, Terapèutica

Matèries (anglès)

Multiple myeloma, Therapeutics

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

ROSIÑOL DACHS, Laura, HEBRAUD, Benjamin, ORIOL, Albert, COLIN, Anne laurène, RÍOS TAMAYO, Rafael, HULIN, Cyrille, BLANCHARD, María jesús, CAILLOT, Denis, SUREDA, Anna, HERNÁNDEZ, Miguel teodoro, ARNULF, Bertrand, MATEOS, Maria victoria, MACRO, Margaret, SAN MIGUEL, Jesús, BELHADJ, Karim, LAHUERTA, Juan josé, GARELIK, M. brigid, BLADÉ, Joan, MOREAU, Philippe. Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma. _Frontiers in Oncology_. 2023. Vol. 13. [consulta: 25 de gener de 2026]. ISSN: 2234-943X. [Disponible a: https://hdl.handle.net/2445/205802]

Exportar metadades

JSON - METS

Compartir registre